Citi Sticks to Its Buy Rating for ProKidney (PROK)
In a report released today, from Citi maintained a Buy rating on ProKidney, with a price target of $9.00. The company’s shares closed yesterday at $3.73.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Currently, the analyst consensus on ProKidney is a Moderate Sell with an average price target of $3.00.
The company has a one-year high of $4.92 and a one-year low of $0.46. Currently, ProKidney has an average volume of 6.85M.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PROK in relation to earlier this year. Most recently, in April 2025, Carso De-C Inmobiliaria, a Major Shareholder at PROK bought 387,393.00 shares for a total of $275,049.03.
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- Why Is ProKidney Stock (PROK) Up 60% Today?
- ProKidney’s Hold Rating: Balancing Promising Phase 2 Results with Future Uncertainties
- Hold Rating for ProKidney Amid Promising Phase 2 Results and Regulatory Uncertainty
- ProKidney price target raised to $9 from $6 at Citi
- ProKidney move after REACT update ‘looks overdone,’ says BofA
